randomized clinical trials given the short duration of follow-up relative to the long latency to incident late effects. Simulation models offer one avenue for estimating an individual’s risk for a given late effect and can be integrated into shared decision-making
Search Results
Matthew J. Ehrhardt, Jamie E. Flerlage, Saro H. Armenian, Sharon M. Castellino, David C. Hodgson, and Melissa M. Hudson
Julia T. van Groningen, Pieter van Hagen, Rob A.E.M. Tollenaar, Jurriaan B. Tuynman, Perla J. Marang-van de Mheen, Pascal G. Doornebosch, Pieter J. Tanis, Eelco J.R. de Graaf, and on behalf of the Dutch Colorectal Audit
and performance of cTME after neoadjuvant therapy. When discussing treatment options with an individual patient after local excision, shared decision-making may lead to refraining from cTME. Several factors may contribute to this: first, patient
Paul J. Speicher, Lin Gu, Xiaofei Wang, Matthew G. Hartwig, Thomas A. D'Amico, and Mark F. Berry
-negative NSCLC in a nontrial setting, which can improve the shared decision-making process and better inform treatment recommendations. In this study, 900 patients aged 70 years or older were given AC. Although there are no specific guidelines for the treatment
Simon D. Fung-Kee-Fung, Sima P. Porten, Maxwell V. Meng, and Michael Kuettel
expectancy compared with other treatment options in properly selected individuals. The decision by patients to choose AS as the initial management strategy is dependent on individual preferences and plays an important role in shared decision-making. Further
Omar Abdel-Rahman
, a shared decision-making process between physicians and patients was recommended) and because screening practices for this subgroup vary across different Canadian jurisdictions, a sensitivity analysis was conducted, repeating all analyses on women
Maxwell T. Vergo and Al B. Benson III
absolute benefits patients may expect from adjuvant therapy in their situation. This can be weighed against known long-term adverse effects from receiving adjuvant chemotherapy, optimizing the shared decision-making process between patient and physician
Andrew T. Kuykendall and Rami Komrokji
routinely recommend cytoreductive therapy; however, this is another situation in which shared decision-making is vital. Broadly speaking, the lack of consensus regarding the impact of platelet count in ET suggests this is a complex relationship that is
Peter D. Stetson, Nadine J. McCleary, Travis Osterman, Kavitha Ramchandran, Amye Tevaarwerk, Tracy Wong, Jessica M. Sugalski, Wallace Akerley, Annette Mercurio, Finly J. Zachariah, Jonathan Yamzon, Robert C. Stillman, Peter E. Gabriel, Tricia Heinrichs, Kathleen Kerrigan, Shiven B. Patel, Scott M. Gilbert, and Everett Weiss
, including whether it is used to facilitate shared decision-making between providers and patients. We also did not obtain the technical or operational specifics regarding how those centers that have had the most success with PGHD integration have accomplished
Aysegul A. Sahin, Timothy D. Gilligan, and Jimmy J. Caudell
undergo surveillance unless there is compelling reason not to. However, patients with larger tumors may prefer radiation or chemotherapy if they know they have a higher risk of relapse. So tumor size can facilitate shared decision-making.” The other area
Presenters: Benjamin O. Anderson and Janice A. Lyons
, and whose RT can be limited to the breast and not include the nodes, Dr. Lyons added. She emphasized that shared decision-making is critical in situations such as this. “The patient may want to accept a higher risk of locoregional recurrence versus
